{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:04:39Z","timestamp":1789167879607,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00210-025-04005-1","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:46:44Z","timestamp":1742204804000},"page":"11989-12001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FOXD1-activated ANXA3 facilitates cisplatin resistance of lung cancer cells via promoting ANXA4 expression"],"prefix":"10.1007","volume":"398","author":[{"given":"Qing","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"1","key":"4005_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12885-021-07957-8","volume":"21","author":"KH Bond","year":"2021","unstructured":"Bond KH, Fetting JL, Lary CW, Emery IF, Oxburgh L (2021) FOXD1 regulates cell division in clear cell renal cell carcinoma. BMC Cancer 21(1):312","journal-title":"BMC Cancer"},{"issue":"9","key":"4005_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/s41419-022-05213-w","volume":"13","author":"K Cai","year":"2022","unstructured":"Cai K, Chen S, Zhu C, Li L, Yu C, He Z, Sun C (2022) FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis. Cell Death Dis 13(9):765","journal-title":"Cell Death Dis"},{"key":"4005_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2020.11.046","volume":"503","author":"S Chen","year":"2021","unstructured":"Chen S, Yang M, Wang C, Ouyang Y, Chen X, Bai J, Hu Y, Song M, Zhang S, Zhang Q (2021) Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma. Cancer Lett 503:43\u201353","journal-title":"Cancer Lett"},{"issue":"6","key":"4005_CR4","volume":"1878","author":"L Cheng","year":"2023","unstructured":"Cheng L, Yan H, Liu Y, Guan G, Cheng P (2023) Dissecting multifunctional roles of forkhead box transcription factor D1 in cancers. Biochim Biophys Acta 1878(6):188986","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"4005_CR5","doi-asserted-by":"publisher","first-page":"7440","DOI":"10.21037\/tcr-20-994","volume":"9","author":"K Du","year":"2020","unstructured":"Du K, Ren J, Fu Z, Wu X, Zheng J, Li X (2020) ANXA3 is upregulated by hypoxia-inducible factor 1-alpha and promotes colon cancer growth. Transl Cancer Res 9(12):7440\u20137449","journal-title":"Transl Cancer Res"},{"issue":"1","key":"4005_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3892\/or.2023.8571","volume":"50","author":"WQ Feng","year":"2023","unstructured":"Feng WQ, Zhang YC, Gao H, Li WC, Miao YM, Xu ZF, Xu ZQ, Zhao JK, Zheng MH, Zong YP et al (2023) FOXD1 promotes chemotherapy resistance by enhancing cell stemness in colorectal cancer through beta-catenin nuclear localization. Oncol Rep 50(1):134","journal-title":"Oncol Rep"},{"issue":"10","key":"4005_CR7","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2021.1117","volume":"325","author":"USPST Force","year":"2021","unstructured":"Force USPST, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA et al (2021) Screening for lung cancer: US preventive services task force recommendation statement. JAMA 325(10):962\u2013970","journal-title":"JAMA"},{"issue":"11","key":"4005_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078610","volume":"8","author":"E Gaudio","year":"2013","unstructured":"Gaudio E, Paduano F, Spizzo R, Ngankeu A, Zanesi N, Gaspari M, Ortuso F, Lovat F, Rock J, Hill GA et al (2013) Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel. PLoS ONE 8(11):e78610","journal-title":"PLoS ONE"},{"issue":"21","key":"4005_CR9","doi-asserted-by":"publisher","first-page":"29927","DOI":"10.18632\/oncotarget.9179","volume":"7","author":"E Gaudio","year":"2016","unstructured":"Gaudio E, Paduano F, Ngankeu A, Ortuso F, Lovat F, Pinton S, D\u2019Agostino S, Zanesi N, Aqeilan RI, Campiglia P et al (2016) A Fhit-mimetic peptide suppresses annexin A4-mediated chemoresistance to paclitaxel in lung cancer cells. Oncotarget 7(21):29927\u201329936","journal-title":"Oncotarget"},{"key":"4005_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM (2019) Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 135:196\u2013204","journal-title":"Lung Cancer"},{"issue":"12","key":"4005_CR11","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/j.jtho.2021.07.018","volume":"16","author":"BH Herzog","year":"2021","unstructured":"Herzog BH, Devarakonda S, Govindan R (2021) Overcoming chemotherapy resistance in SCLC. J Thorac Oncol 16(12):2002\u20132015","journal-title":"J Thorac Oncol"},{"issue":"12","key":"4005_CR12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s13258-023-01461-y","volume":"45","author":"J Huang","year":"2023","unstructured":"Huang J, Wei W, Kang F, Tan S, Li Y, Lu X, Wang N (2023) ANXA3, associated with YAP1 regulation, participates in the proliferation and chemoresistance of cervical cancer cells. Genes Genomics 45(12):1575\u20131586","journal-title":"Genes Genomics"},{"issue":"7","key":"4005_CR13","first-page":"3741","volume":"24","author":"YF Jin","year":"2020","unstructured":"Jin YF, Huang YT, Chen PF (2020) ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin. Eur Rev Med Pharmacol Sci 24(7):3741\u20133748","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"4005_CR14","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1007\/s12010-023-04595-7","volume":"196","author":"R Kaur","year":"2024","unstructured":"Kaur R, Suresh PK (2024) Chemoresistance mechanisms in non-small cell lung cancer-opportunities for drug repurposing. Appl Biochem Biotechnol 196(7):4382\u20134438","journal-title":"Appl Biochem Biotechnol"},{"issue":"3","key":"4005_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3892\/etm.2023.11826","volume":"25","author":"JY Kim","year":"2023","unstructured":"Kim JY, Jung EJ, Kim JM, Son Y, Lee HS, Kwag SJ, Park JH, Cho JK, Kim HG, Park T et al (2023) MiR-221 and miR-222 regulate cell cycle progression and affect chemosensitivity in breast cancer by targeting ANXA3. Exp Ther Med 25(3):127","journal-title":"Exp Ther Med"},{"issue":"16","key":"4005_CR16","doi-asserted-by":"publisher","first-page":"8885","DOI":"10.3390\/ijms22168885","volume":"22","author":"J Kryczka","year":"2021","unstructured":"Kryczka J, Kryczka J, Czarnecka-Chrebelska KH, Brzezianska-Lasota E (2021) Molecular mechanisms of chemoresistance induced by cisplatin in NSCLC cancer therapy. Int J Mol Sci 22(16):8885","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4005_CR17","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1159\/000495962","volume":"51","author":"D Li","year":"2018","unstructured":"Li D, Fan S, Yu F, Zhu X, Song Y, Ye M, Fan L, Lv Z (2018) FOXD1 promotes cell growth and metastasis by activation of vimentin in NSCLC. Cell Physiol Biochem 51(6):2716\u20132731","journal-title":"Cell Physiol Biochem"},{"issue":"12","key":"4005_CR18","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3390\/cancers11121897","volume":"11","author":"CH Li","year":"2019","unstructured":"Li CH, Chang YC, Hsiao M (2019) Liang SM (2019) FOXD1 and Gal-3 form a positive regulatory loop to regulate lung cancer aggressiveness. Cancers 11(12):1897","journal-title":"Cancers"},{"issue":"13","key":"4005_CR19","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","volume":"136","author":"C Li","year":"2023","unstructured":"Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y, Li L (2023) Global burden and trends of lung cancer incidence and mortality. Chin Med J 136(13):1583\u20131590","journal-title":"Chin Med J"},{"key":"4005_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.molimm.2024.01.006","volume":"167","author":"J Liang","year":"2024","unstructured":"Liang J, Zhang J, Fan J, Chen S, Wu W (2024) ANXA3 interference inactivates ERK\/ELK1 pathway to mitigate inflammation and apoptosis in sepsis-associated acute lung injury. Mol Immunol 167:25\u201333","journal-title":"Mol Immunol"},{"issue":"4","key":"4005_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/dvdy.545","volume":"252","author":"SN Lipp","year":"2023","unstructured":"Lipp SN, Jacobson KR, Schwaderer AL, Hains DS, Calve S (2023) FOXD1 is required for 3D patterning of the kidney interstitial matrix. Dev Dyn 252(4):463\u2013482","journal-title":"Dev Dyn"},{"issue":"6","key":"4005_CR22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3892\/ol.2021.13095","volume":"22","author":"C Liu","year":"2021","unstructured":"Liu C, Li N, Liu G, Feng X (2021a) Annexin A3 and cancer. Oncol Lett 22(6):834","journal-title":"Oncol Lett"},{"key":"4005_CR23","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.2147\/CMAR.S251679","volume":"13","author":"Q Liu","year":"2021","unstructured":"Liu Q, Wang S, Pei G, Yang Y, Min X, Huang Y, Liu J (2021b) Impact analysis of miR-1253 on lung cancer progression through targeted regulation of ANXA3. Cancer Manag Res 13:1767\u20131776","journal-title":"Cancer Manag Res"},{"issue":"2","key":"4005_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","volume":"44","author":"HY Min","year":"2021","unstructured":"Min HY, Lee HY (2021) Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharmacal Res 44(2):146\u2013164","journal-title":"Arch Pharmacal Res"},{"issue":"11","key":"4005_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080359","volume":"8","author":"T Mogami","year":"2013","unstructured":"Mogami T, Yokota N, Asai-Sato M, Yamada R, Koizume S, Sakuma Y, Yoshihara M, Nakamura Y, Takano Y, Hirahara F et al (2013) Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. PLoS ONE 8(11):e80359","journal-title":"PLoS ONE"},{"issue":"6","key":"4005_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3892\/ijo.2021.5208","volume":"58","author":"AP Morelli","year":"2021","unstructured":"Morelli AP, Tortelli TC Jr, Pavan ICB, Silva FR, Granato DC, Peruca GF, Pauletti BA, Domingues RR, Bezerra RMN, De Moura LP et al (2021) Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways. Int J Oncol 58(6):28","journal-title":"Int J Oncol"},{"issue":"17","key":"4005_CR27","doi-asserted-by":"publisher","first-page":"7776","DOI":"10.18632\/oncotarget.2306","volume":"5","author":"A Morimoto","year":"2014","unstructured":"Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M et al (2014) Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Oncotarget 5(17):7776\u20137787","journal-title":"Oncotarget"},{"issue":"1","key":"4005_CR28","first-page":"261","volume":"35","author":"S Nakayama","year":"2015","unstructured":"Nakayama S, Soejima K, Yasuda H, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Yamaguchi N, Hamamoto J et al (2015) FOXD1 expression is associated with poor prognosis in non-small cell lung cancer. Anticancer Res 35(1):261\u2013268","journal-title":"Anticancer Res"},{"issue":"6","key":"4005_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3892\/mco.2022.2544","volume":"16","author":"A Ozturk","year":"2022","unstructured":"Ozturk A (2022) Role of annexin A3 in breast cancer (review). Mol Clin Oncol 16(6):111","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"4005_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/mc.22126","volume":"54","author":"QZ Pan","year":"2015","unstructured":"Pan QZ, Pan K, Weng DS, Zhao JJ, Zhang XF, Wang DD, Lv L, Jiang SS, Zheng HX, Xia JC (2015) Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma. Mol Carcinog 54(8):598\u2013607","journal-title":"Mol Carcinog"},{"issue":"1","key":"4005_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/CCO.0000000000000592","volume":"32","author":"R Pirker","year":"2020","unstructured":"Pirker R (2020) Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. Curr Opin Oncol 32(1):63\u201367","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"4005_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2174\/1570180819666220510133408","volume":"20","author":"A Rajendra","year":"2023","unstructured":"Rajendra A, Anurag Kumar S, Gaurav M, Anand M, Neerupma D, Harsha K, Bhupesh S, Niraj Kumar J, Harish D, Kamal D et al (2023) Diagnosis and clinical aspects of lung cancer: a special emphasis on drug targeting to cancer cells through nanoparticles. Lett Drug Discov 20(5):499\u2013516","journal-title":"Lett Drug Discov"},{"issue":"5","key":"4005_CR33","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2174\/1570180820666230228103903","volume":"21","author":"D Rasit","year":"2024","unstructured":"Rasit D (2024) Magnetic nanoparticles with aspects of their use in cancer therapy. Lett Drug Discov 21(5):847\u2013857","journal-title":"Lett Drug Discov"},{"issue":"5","key":"4005_CR34","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/cas.13998","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao L, Meng Z, Wu X, Xu M, Xu K (2019) Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Cancer Sci 110(5):1609\u20131620","journal-title":"Cancer Sci"},{"issue":"1","key":"4005_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/CCO.0000000000000703","volume":"33","author":"F Wu","year":"2021","unstructured":"Wu F, Wang L, Zhou C (2021) Lung cancer in China: current and prospect. Curr Opin Oncol 33(1):40\u201346","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"4005_CR36","doi-asserted-by":"publisher","first-page":"14585","DOI":"10.1002\/jcb.28720","volume":"120","author":"R Xu","year":"2019","unstructured":"Xu R, Yin J, Zhang Y, Zhang S (2019) Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway. J Cell Biochem 120(9):14585\u201314593","journal-title":"J Cell Biochem"},{"issue":"1","key":"4005_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2012.03.144","volume":"421","author":"T Yamashita","year":"2012","unstructured":"Yamashita T, Nagano K, Kanasaki S, Maeda Y, Furuya T, Inoue M, Nabeshi H, Yoshikawa T, Yoshioka Y, Itoh N et al (2012) Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem Biophys Res Commun 421(1):140\u2013144","journal-title":"Biochem Biophys Res Commun"},{"key":"4005_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.716415","volume":"8","author":"L Yang","year":"2021","unstructured":"Yang L, Lu P, Yang X, Li K, Qu S (2021) Annexin A3, a calcium-dependent phospholipid-binding protein: implication in cancer. Front Mol Biosci 8:716415","journal-title":"Front Mol Biosci"},{"issue":"5","key":"4005_CR39","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2741\/4432","volume":"21","author":"H Yao","year":"2016","unstructured":"Yao H, Sun C, Hu Z, Wang W (2016) The role of annexin A4 in cancer. Front Biosci (Landmark Ed) 21(5):949\u2013957","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"4005_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/09553002.2022.2110321","volume":"99","author":"LB Zablotska","year":"2023","unstructured":"Zablotska LB, Richardson DB, Golden A, Pasqual E, Smith B, Rage E, Demers PA, Do M, Fenske N, Deffner V et al (2023) The epidemiology of lung cancer following radiation exposure. Int J Radiat Biol 99(3):569\u2013580","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"4005_CR41","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.bbrc.2014.11.064","volume":"456","author":"YF Zhao","year":"2015","unstructured":"Zhao YF, Zhao JY, Yue H, Hu KS, Shen H, Guo ZG, Su XJ (2015) FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochem Biophys Res Commun 456(1):232\u2013237","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"4005_CR42","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s11418-018-1211-0","volume":"72","author":"MD Zheng","year":"2018","unstructured":"Zheng MD, Wang ND, Li XL, Yan J, Tang JH, Zhao XH, Zhang Z (2018) Toosendanin mediates cisplatin sensitization through targeting annexin A4\/ATP7A in non-small cell lung cancer cells. J Nat Med 72(3):724\u2013733","journal-title":"J Nat Med"},{"issue":"21","key":"4005_CR43","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.7150\/jca.31191","volume":"10","author":"L Zhou","year":"2019","unstructured":"Zhou L, Jia S, Ding G, Zhang M, Yu W, Wu Z, Cao L (2019) Down-regulation of miR-30a-5p is associated with poor prognosis and promotes chemoresistance of gemcitabine in pancreatic ductal adenocarcinoma. J Cancer 10(21):5031\u20135040","journal-title":"J Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04005-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:02:30Z","timestamp":1758301350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04005-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["4005"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04005-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the ethical review committee of the 926 Hospital of the Joint Support Force of the Chinese People\u2019s Liberation Army. Consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics declaration"}},{"value":"Every human concerned in this experiment\/all subjects provided written informed consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Animal studies were performed in compliance with the ARRIVE guidelines and the Basel Declaration. All animals received humane care according to the National Institutes of Health (USA) guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"The research has been carried out in accordance with the World Medical Association Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights statements"}},{"value":"All of us authors agree to publish this article in this journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}